Introduction/Background Ovarian cancer in patients with somatic BRCA mutation is described to have better outcomes, as they are more responsive to adjuvant treatments. The aim of this study is to analyse the recurrence and mortality rates of these patients, and compare them with the non-mutated patients.

Methodology Retrospective observational study of patients who underwent surgery at our center between 2019 and 2023 with diagnosis of epithelial ovarian cancer (EOC). Statistical analysis was performed using SPSS.

Results 147 patients were studied. The mean age was 62.4 years (22–86). The surgery performed was primary in 55.8% of the patients, interval surgery in 40.1%, and exploratory in 6.8%. 44 patients presented BRCA mutation (29.9%), 81 were negative (55.1%), 7 presented homologous recombination deficiency (HRD) (4.8%) and 15 patients were not studied (10.2%). 78.2% of tumors were high-grade serous carcinomas, 9.5% endometrioids, 4.8% mucinous, 4.1% clear cell and 3.4% low-grade serous carcinomas. At the time of the surgery, 31 cases were stage I (21.1%), 8 stage II (5.4%), 68 stage III (46.3%) and 40 stage IV (27.2%). Optimal cytoreduction was achieved in 115 patients (78.2%). The BRCA negative group presented greater mortality rates compared to the BRCA mutated group (25.9% vs 9.1%, p=0.03). The recurrence rate was also higher in the BRCA negative patients (46.9% vs 29.5%), but without statistical significance (p=0.38). The HRD group did not present any cases of death, and 2 patients recurred (28.6%), but the follow-up in this group was less than 2 years. The hazard ratio for mortality was 2.85 (95% CI, 1.04 to 7.78; p=0.025) for the patients without de mutation.

Conclusion Patients with a somatic BRCA mutation in the tumor have greater survival with statistical significance. They also have a tendency towards lower recurrence rates. The absence of BRCA mutation in EOC increased the mortality rate by 2.85 times.

Disclosures None of the authors have any conflicts of interest.